138 results about "Isoindoline" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to a compound as shown in a formula (I), pharmaceutically acceptable salt, deuterated substance, stereoisomer, tautomer or a mixture of the pharmaceutically acceptable salt, the deuterated substance, the stereoisomer and the tautomer, and application of the compound as an IKZF1 and IKZF3 double-target immunomodulator.

The application relates to a preparation method of an arylmethoxy isoindoline derivative and belongs to the field of pharmaceutical chemical industry. Specifically, a compound of formula III and a compound of formula II are reacted in an organic solvent in the presence of a reducing agent to generate a compound of formula I. A new preparation route of the arylmethoxy isoindoline derivative is provided, and the preparation route has high yield and high product purity.

The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.

The present disclosure provides a compound of Formula (I'): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and Ri are as defined herein, and methods of making and using same.

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and / or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and / or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.

The present invention relates to an isoindoline compound containing a phenylethoxyalkyleneamine structure, a conjugate thereof, and use thereof. The isoindoline compound containing a phenylethoxyalkyleneamine structure has a structure represented by formula (I). The conjugate thereof has a structure represented by formula (B). The compound of the present invention exhibits increased proliferation inhibition activity for cancer cells and a degradation effect on proteins such as GSPT1, demonstrating practical values.

Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.

The present invention relates to pharmaceutical compounds and formulations comprising said compounds, wherein said compounds have the structure according to Formula I or II. The compounds and formulations are suitable for use as medicaments for the prevention or treatment of diseases or conditions characterized by percutaneous cell dysfunction, detachment and / or loss, for medical treatment for vascular stabilization, for treatment for promoting, restoring or maintaining attachment of percutaneous cells to blood vessels, and / or for the treatment of vascular-related diseases in patients. (I) (II)

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Provided herein are methods of using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-(3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiometer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia / small lymphocytic lymphoma.

Described are compounds, compositions, and methods for treating Tumor Necrosis Factor Receptor-Associated Protein 1 (TRAP 1) related diseases and / or disorders, such as cancer.

Provided herein are formulations, processes, solid forms and methods of use (e.g., methods of treating a hematological malignancy) relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione.

The present invention relates to a pharmaceutically acceptable salt and a crystal form of a tetrahydronaphthalene derivative, and a preparation method. Specifically, the present disclosure provides a pharmaceutically acceptable salt and a crystal form of (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine- 2,6-dione, and a preparation method therefor. The corresponding salt has good stability and can be better used for clinical treatment.

The invention belongs to the field of agricultural science, and discloses a triazolyl isoindolinone compound I. The triazolyl isoindolinone compound I is obtained by using an isoindolinone skeleton as a basis and connecting an amino acid with a triazole ring containing a substituent group to construct an amide structure. The compound is simple in structure, mild in synthesis reaction condition, simple and convenient to operate and high in yield, has good bactericidal activity and can be used for developing agricultural bactericides.

The application discloses a reaction type thermoplastic resin with a large free volume, a preparation method and a bismaleimide resin composition, and belongs to the technical field of polymer material toughening. N 2 a nucleophilic polycondensation reaction to obtain a polyaryletherketone / sulfone copolymer containing a reaction type group, wherein the bisphenol compound is selected from one or more of phenolphthalein, thymolphthalein, bisphenol fluorene and isoindolinone-based bisphenol. The application introduces a bisphenol compound with a large side group into the molecular chain of the thermoplastic resin to construct a large free volume structure, and simultaneously utilizes TGSH to provide an active propenyl group, so that the resin can participate in the curing and cross-linking reaction of bismaleimide. The bismaleimide resin composition using the resin as a toughening agent has a significantly improved toughness after curing.

The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, comprising a 2-(4-(1-hydroxypropane-2-yl)phenyl) isoindoline-1-one compound or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for preventing or treating Parkinson's disease can increase the protein level of PGC-la in the brain of an individual by successfully passing through the blood-brain barrier (BBB).

The present invention relates to an injectable form comprising: (i) At least 1.5 mg / mL of 2-[6-(4- cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone; (ii) a solvent selected from the group consisting of polyethylene glycol 300 (PEG300), polyethylene glycol 400 (PEG400), and mixtures thereof; and (iii) a co-solvent selected from the group consisting of PEG300, PEG400, propylene glycol, and mixtures thereof.

Provided herein are methods of treating and / or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione ("Compound A, A-S, or A- R"), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.

This application relates to the field of biomedical technology, and more specifically to the compound represented by formula (I), its pharmaceutically acceptable salt, its deuterated compound, its stereoisomer, its tautomer, or mixtures thereof, and the use of said compound as an immunomodulator for dual targeting of IKZF1 and IKZF3. TIFF2026511128000306.tif30170

The application belongs to the technical field of organic synthesis, and particularly relates to a kind of bromine-containing isoindoline-1-ketone compound and preparation method thereof.The preparation method of the bromine-containing isoindoline-1-ketone compound uses commercially available aldehyde-derived imine as raw material, is reacted with aryl bromide oxazoline compound under butyl lithium condition, and then is subjected to acid-mediated cascade cyclization process, to efficiently construct isoindoline-1-ketone skeleton.The isoindoline-1-ketone compound can be directly used as an organic catalyst, the N-H functional group remaining in the structure of the isoindoline-1-ketone compound has reactivity, can be coupled with other bioactive molecules as a key connection site, to construct functional derivatives, the amide carbonyl group thereof can be further reduced, to be converted into pyrrolidine structural unit, and the structure itself can be used as a catalytically active center, to expand its application in the field of catalysis.

An isoindoline derivative of formulawhereinX is N, C—CN or C—COR2;Y is a radical having an acidic group or a basic group;R1 is independently from one another halogen or C1-C4-alkyl, said alkyl is unsubstituted or substituted with halogen;R2 is C1-C4-alkyl, said alkyl is unsubstituted or substituted with halogen; andn is 0, 1, 2, 3 or 4,with the proviso that Y does not include an acidic group if X is C—CN or C—COR2, and compositions containing the same are provided. The isoindoline derivative and the pigment composition are suitable, for example, for coloring high molecular mass organic material, especially paints, printing inks, resist formulations for color filter applications, electrophotographic toners, cosmetics, plastics, films or fibers.

Formula (I): TIFF2026500094000217.tif37107 [Wherein R is and rings A, L, R1, R2, R3, m, and n are defined in this disclosure], its stereoisomers, its tautomers, or salts thereof. Also disclosed are methods of using the compounds to decrease cyclin E1 levels; and pharmaceutical compositions containing the compounds. These compounds are useful for treating proliferative diseases (e.g., cancer).

Disclosed is a compound of formula (I): or a stereoisomer, tautomer or salt thereof. Also disclosed are methods of using such compounds to reduce the level of the IKZF1-4 protein; and a pharmaceutical composition comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer. (I)